These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 6404852

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Resistance to gentamicin, tobramycin and amikacin among clinical isolates of bacteria.
    Moellering RC, Wennersten C, Kunz LJ, Poitras JW.
    Am J Med; 1977 Jun; 62(6):873-81. PubMed ID: 868901
    [Abstract] [Full Text] [Related]

  • 3. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns.
    Acar JF, Witchitz JL, Goldstein F, Talbot JN, Le Goffic F.
    J Infect Dis; 1976 Nov; 134 SUPPL():S280-5. PubMed ID: 825587
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics.
    Dámaso D, Moreno-López M, Martínez-Beltrán J, García-Iglesias MC.
    J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy.
    Saavedra S, Vera D, Ramírez-Ronda CH.
    Am J Med; 1986 Jun 30; 80(6B):65-70. PubMed ID: 3014877
    [Abstract] [Full Text] [Related]

  • 8. Amikacin-resistant gram-negative bacilli: correlation of occurrence with amikacin use.
    Levine JF, Maslow MJ, Leibowitz RE, Pollock AA, Hanna BA, Schaefler S, Simberkoff MS, Rahal JJ.
    J Infect Dis; 1985 Feb 30; 151(2):295-300. PubMed ID: 3918124
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin.
    Ruiz-Palacios GM, Ponce de Leon S, Sifuentes J, Ponce de Leon S, Calva JJ, Huazano F, Ontiveros C, Ojeda F, Bobadilla M.
    Am J Med; 1986 Jun 30; 80(6B):71-5. PubMed ID: 3089006
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro evaluation of N-formimidoyl thienamycin (MK0787) combined with amikacin against gram-negative bacilli and Staphylococcus aureus.
    Díez Enciso M, Mateos Lindemann M, Gutiérrez Altés A.
    Antimicrob Agents Chemother; 1982 Dec 30; 22(6):1064-6. PubMed ID: 6818899
    [Abstract] [Full Text] [Related]

  • 16. [Antimicrobial effectiveness of sisomicin. I: In vitro activity of sisomicin compared with gentamicin, tobramycin, amikacin and kanamycin (author's transl)].
    Schassan HH.
    Infection; 1976 Dec 30; 4(2):35-41. PubMed ID: 789246
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Antibacterial activity of amikacin towards gentamicin-resistant, Gram-negative bacilli].
    Nicoletti G, Russo G, Toscano MA, Gismondo MR.
    Boll Ist Sieroter Milan; 1979 Jan 31; 57(6):713-7. PubMed ID: 121911
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Resistance surveillance programs and the incidence of gram-negative bacillary resistance to amikacin from 1967 to 1985.
    Gerding DN, Larson TA.
    Am J Med; 1986 Jun 30; 80(6B):22-8. PubMed ID: 3089003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.